Treat in Biological Technology

A Swiss Team Uses Transcranial MR-Guided Focused Ultrasound to Treat Patients With Functional Brain Disorders

TIRAT CARMEL, Israel, July 14 /PRNewswire/ -- InSightec Ltd. today announced that a team at the University Children's Hospital Zurich has completed a feasibility study testing the use of non-invasive transcranial MR-guided focused ultrasound surgery (MRgFUS) for the treatment of...

Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia

PLYMOUTH, Mass., July 9 /PRNewswire/ -- Harvest Technologies Corp. ( www.harvesttech.com ) announced today that the company sponsored 60-patient clinical trial conducted at Sri Ramachandra Medical Center in Chennai, India using the company's BMAC System to treat patients with non-reconstructable...

Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University

Calvert Research, LLC (a unit of Calvert Holdings, Inc.) today announced the execution of a license agreement with Tulane University granting Calvert Research (through its wholly owned subsidiary, Calvert T1, LLC) certain rights to issued patents and patent applications covering a technology plat...

Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma

JERUSALEM, June 3 /PRNewswire/ -- The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the Excel study. Participating clinical sites include, in alphabetical order: ...

Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bo...

Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury

SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN)( http://www.BMSN.us ) and Entest BioMedical Inc., its wholly owned subsidiary, announced today they have jointly submitted a Project Summary Report to the U.S. Army Medical Research and Mater...

CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies

Peptide-based vaccines could prove efficacious for both prophylactic and therapeutic treatments VIENNA, Va., April 28 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM ) announced today that preclinical studies have demonstrated that vaccines utilizing its proprietary L.E.A.P.S....

Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients.

- Journal of Neuroscience paper describes role of Zinc in developing Alzheimer's - MELBOURNE, Australia, April 1 /PRNewswire-FirstCall/ -- Prana Biotechnology (ASX:PBT; Nasdaq: PRAN ) today announced that an independent study conducted by researchers at the University of California, Irvine...

Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial

Central Texas man receives groundbreaking therapy days after heart attack AUSTIN, Texas, March 31 /PRNewswire/ -- On March 30, the Heart Hospital of Austin treated the first patient in the world enrolled in a groundbreaking Phase II study designed to test the effectiveness and safety of a...

Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA

Application Includes Data from a Comparative Trial in Anterior Uveitis TAMPA, Fla., March 16 /PRNewswire/ -- Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(...

Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS

Therapeutic Approach Provides HIV-Resistant Immune Cells RICHMOND, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that its collaborators at the University of Pennsylvania have opened a Phase 1 clinical trial to evaluate SB-728-T for the ...

Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease

HAMBURG, Germany and STOCKHOLM, January 21 /PRNewswire/ -- Richter-Helm BioLogics GmbH & Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Athera's novel product for prevention of plaque rupture and athero-thrombosis through binding of t...

Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems

Fast form of precise radiotherapy targets tumors quickly and accurately while minimizing exposure of surrounding healthy tissue PALO ALTO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- During his annual physical check-up in March, David Kelver's doctor noticed he'd never had his tonsils out,...

BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes

Preservation with BioLife's Proprietary, Next Generation, Biopreservation Media Resulted in Increased Yield and Quality of Insulin-Producing Islet Cells BOTHELL, Wash., Oct. 24 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (OTC Bulletin Board: BLFS), a leadi...

Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During 'Live' Case at the Paris Cardiovascular Interventions Course (Francophone) 2008

Research Shows New Class of Stent Effective in Preventing Thrombosis, Restenosis, and Reocclusion PARIS, Oct. 1 /PRNewswire/ -- CeloNova BioSciences, Inc., today announced that Masahiko Ochiai MD, Associate Professor, Division of Cardiology, Yokohama Hospital, Kanagawa, J...

Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)

Total Value of the Commitment to the CGI is an Estimated $210 Million Crofelemer, Once Approved for Children, Could Aid in Treating Diarrhoel Diseases That Kill An Estimated 2.5 million Children Each Year NEW YORK, Sept. 25 /PRNewswire-USNewswire/ -- Napo Pharmaceuticals, Inc., ("Napo") of...

Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic

LOS ANGELES, California and GUANGZHOU, China, August 12 /PRNewswire-FirstCall/ -- - Major Threat Treatable With StatC(TM); FDA-Approved Drugs to Begin Testing in U.S. Animal Models An internationally renowned avian influenza expert today hailed "encouraging and exciting" results from exper...

Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells

DALLAS, June 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that the Company gave an oral presentation yesterday on its monoclonal antibody product, Angiolix(R), at the 7th International Congress on Recombinant Antibodies, held in Dublin, Ireland...

Novel compound may treat acute diarrhea

In a development that may lessen the epidemic of diarrhea-related deaths among children in developing countries, scientists in the laboratory of Nobel Laureate Ferid Murad, M.D., Ph.D., at The University of Texas Health Science Center at Houston have discovered a novel compound that might lead to ...

AMITIZA(R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women

AMITIZA 8 mcg dose is the only widely available FDA-approved prescription medication for Irritable Bowel Syndrome with Constipation BETHESDA, Md., and DEERFIELD, Ill., May 27 /PRNewswire-FirstCall/ -- Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP ) and Takeda Pharmaceuticals North America,...

Top Cancer Hospitals in Denmark and Netherlands First in Europe to Treat Patients With RapidArc(TM) Radiotherapy

New technology from Varian Medical Systems delivers faster image-guided intensity-modulated radiotherapy (IMRT) to target tumors while sparing more healthy tissue COPENHAGEN, Denmark and AMSTERDAM, Netherlands, May 14 /PRNewswire-FirstCall/ -- Doctors in Denmark and...

Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS

JADO Technologies' Scientists and Collaborators Publish Study in Science DRESDEN, Germany, April 25 /PRNewswire/ -- JADO Technologies GmbH, the leading developer of RAFT intervention therapeutics, announced today the publication of a paper in Science demonstrating a potential novel strategy fo...

FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults

Within the First Eight Months Since its Introduction in the United States, VYVANSE has Achieved Over One Million Prescriptions In a Clinical Study With Adults, VYVANSE was Shown to Significantly Improve the Symptoms of ADHD (Inattention, Hyperactivity and Impulsivity)(1) BASINGSTOKE, ...

CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide

More Than 5,000 Lung Cancer Patients Treated With CyberKnife System to Date SUNNYVALE, Calif., March 26 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that approximately 90 percent of CyberKnife centers worldwide are...

Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension

RESEARCH TRIANGLE PARK, N.C., Feb. 20 /PRNewswire/ -- Addrenex Pharmaceuticals has reached its first milestone accomplishment this year with the filing of a new drug application (NDA) for its first drug, CloniBID, to treat hypertension. Upon approval from the Food and Drug Administration, Addr...

AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation

WEST CHESTER, Ohio, Feb. 11 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC ), a medical device company and a leader in cardiac surgical ablation products, today announced that the first patient was successfully treated in AtriCure's ABLATE clinical trial. Dr. Richard Kaplon, a well-kn...

Difficult to Treat Erectile Dysfunction Patients

Real Medicine Now CHERRY HILL, N.J., Jan. 7 /PRNewswire/ -- TriMix Laboratories LLC today announced the introduction of TriMix-gel(TM). TriMix-gel(TM) has been suggested as an alternative for patients who fail on Viagra(R) type pills and cannot or will not self injec...

Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma

Summary: Genmab's Partner, Roche has Initiated a Phase II study of R1507 for the Treatment of Sarcoma COPENHAGEN, Denmark, December 20 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that its partner, Roche has initiated a Phase II clinical study of R1507 f...

BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease

NOVATO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and IGAN Biosciences announced today that they have initiated a program to develop an IgA protease for treating IgA nephropathy. IgA proteases have been shown to cleave IgA complexes, the depos...

REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide

HORSHAM, Pa. and KENILWORTH, N.J., Nov. 6 /PRNewswire/ -- Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now been treated with REMICADE(R) (infliximab), the leading anti-tumor necrosis factor (TN...

Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer

SANTA MONICA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced an update on its testing of Rh-Apo2L, the next large-scale product to be launched by the Company into the China market. Aida previously announced that it had successful...

Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases

- Includes license of two antisense drugs in development targeting glucagon receptor and glucocorticoid receptor - Includes research collaboration to identify antisense drugs to inhibit additional targets to treat metabolic diseases - Conference call webcast Thursd...

FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania

TITUSVILLE, N.J., Aug. 22 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved RISPERDAL(R) (risperidone) for the treatment of schizophrenia in adolescents ages 13-17 and for the short-term treatment of bipolar mania associated with manic or mixed episodes of bipolar I di...

ConjuGon gets $730K to treat infections

Madison, Wis. - Injured soldiers in Iraq and Afghanistan are becoming infected with bacteria that conventional antibiotics cannot treat, but a Madison-based company is developing counter-measures. With a $730,000 Small Business Innovation Research (SBIR) grant from the U.S. Army in hand, Co...

Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading

...urnal of Medicine claim to demonstrate that vertebroplasty, a procedure to treat some painful spine fractures, is not effective. According to several autho...ncluded that "Percutaneous Vertebroplasty is a safe and effective method to treat VCF. An immediate improvement in pain is expected for most patients, and di...

Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product

...tart later this year, will utilize the Company's Cartilage Repair Device, which consists of a proprietary bi-phasic, bioresorbable implant designed to treat chondral lesions. The Company recently submitted a design dossier for CE Mark approval for its cartilage repair device; approval is expected at the en...

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

...ed from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related fo...

NeurogesX Reports Second Quarter 2009 Results

... second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the design and ti...

AOBO Announces New Product Launch

... NEW YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ -- - Jingwei Capsules treat Allergy Symptoms - - Complements Established Boke Nasal Spray Brand - - Diversifies Product Offering with Capsule Formulatio...

Viral Genetics Creates Subsidiary to Develop Cancer Therapy

...als. He served as product leader for that company's lead cancer compound to treat prostate and breast cancer. "Metabolic disruption technology holds...Marino, California, Viral Genetics discovers and develops drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its th...